hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 23:30:23 - browse：9

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Neuroscience’s long legacy of racism

knowledge

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Leading voice in opioid treatment defends methadone clinic system

Anthos stroke drug appears safer than common blood thinner

Hospitals look to new technology to keep health care workers safe

A daunting task: navigating dual Medicare, Medicaid eligibility

Wikipedia

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

UnitedHealth increases loan offers after Change Healthcare outage

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Walensky prepares to leave CDC — and Congress — behind

SCOTUS questions limit to govt efforts to fight misinformation

In age of alternative facts, a scholarly course on calling out crap

Gene editing the human germline: What are the risks?

New air purifier tech could be key to improving indoor air quality

CVS Caremark has created a new ploy: the drug ‘rebate credit’

entertainment

AstraZeneca to buy developer of next

CVS Caremark has created a new ploy: the drug ‘rebate credit’

SCOTUS questions limit to govt efforts to fight misinformation

Intermittent fasting comes with a heart risk? Not so fast

Creating egg and sperm cells from stem cells raises ethical issues

Hospitals look to new technology to keep health care workers safe

focus

knowledge

entertainment

hotspot